ejpmr, 2023, 10(7), 221-232

SJIF Impact Factor 6.222

EUROPEAN JOURNAL OF PHARMACEUTICAL AND MEDICAL RESEARCH

www.ejpmr.com

Review Article

ISSN 2394-3211

EJPMR

OPHTHALMIC MEDICATED GEL AS A DRUG DELIVERY SYSTEMS: A REVIEW

Nilesh Rajaram Mahajan[1*], Ajit B. Tuwar[2], Prashant B. Patil[3], Prof. Dr. R. S. Bacchav[4]

[1,2]Research Scholar, Kalyani Charitable trust's Ravindra Gambhirrao Sapkal College of Pharmacy, Anjaneri, Nashik 422213.

[3]Assistant Professor, Kalyani Charitable trust's Ravindra Gambhirrao Sapkal College of Pharmacy, Anjaneri, Nashik-422213.

[4]Principal, Kalyani Charitable trust's Ravindra Gambhirrao Sapkal College of Pharmacy, Anjaneri, Nashik-422213.

***Corresponding Author: Nilesh Rajaram Mahajan**

Research Scholar, Kalyani Charitable Trust's Ravindra Gambhirrao Sapkal College of Pharmacy, Anjaneri, Nashik 422213.

Article Received on 14/05/2023 **Article Revised on 04/06/2023** **Article Accepted on 24/06/2023**

ABSTRACT

The goal of ocular therapeutics is to achieve the optimal concentration of the drug at the site of action. This process is carried out mainly due to the precorneal loss, which can prevent the drug from being absorbed properly. In order to improve the effectiveness of the drug, in-situ gel-forming systems can be used. This procedure is very challenging and interesting to implement. The eye is resilient to foreign substances due to its various anatomical and physiological properties. Formulators have to be able to penetrate the protective barriers without causing tissue damage. The various physiological, anatomical, and biotechnological properties of the eye make it resilient to foreign substances. Formulators have to be cognizant of the fact that they have to go through protective barriers without damaging tissue. Ophthalmic Gel maximize contact time, reduce tear dilution, and inhibit nasolacrimal drainage to promote optimal medication absorption. The main drawback of gel is that it causes blurry vision; as a result, it should only be used at night or for treating the outer and corners of the eyelids. The use of suspension as an ocular delivery method is predicated on the idea that particles might stay in the conjunctival sac. Precorneal medication loss can be minimized by utilizing a diffusion-controlled, non-erodible polymeric insert to delay drainage. Due to its complicated administration, inserts main drawback is the lack of patient acceptance. The need for more effective ocular delivery systems is driven by the development of newer, more sensitive diagnostic techniques and treatment substances.

KEYWORD: Ophthalmic, In-situ Gel, polymeric, ocular.

INTRODUCTION

The focus of the current study is a quick overview of quality control procedures for eye medicines according to several pharmacopoeias. distinct pharmacopoeias including IP, BP, and USP have distinct quality control testing for eye medicines. Eye preparations are sterile liquid, semi-solid, or solid medications designed to be injected into the conjunctiva, applied to the eyeball, or both. The eye's architecture, physiology, and biochemistry make it extraordinarily resistant to impurities. The trick for the formulator is to get past the eye's defenses without causing long-term tissue damage. Ophthalmic ointments prevent nasolacrimal drainage, prolong contact time, and reduce tear dilution to maximize drug absorption.[1] In order to control microbial contamination, this research examines the crucial components involved in the production of ophthalmic goods. Its emphasis is on aseptic product dispensing as well as technological and environmental requirements such blow-fill-seal filling and container sealing technologies.[2] In order to control microbial contamination, this research examines the crucial components involved in the production of ophthalmic goods. Its emphasis is on aseptic product dispensing as well as technological and environmental requirements such blow-fill-seal filling and container sealing technologies. Due to the many benefits this polymeric system offers, including ease of administration, decreased frequency of administration, enhanced patient compliance, and comfort, in situ gel systems have attracted a lot of interest in recent years. One or more stimuli, such as pH change, temperature modulation, and solvent exchange, cause in situ gel formation. Among these ocular formulations, 90% of them are used as solutions and suspensions.[3] However, topical eye solutions are the more convenient and easy mode of drug application in the eyes, and hence, traditionally used as a conventional formulation to the eye against many eye diseases, bioavailability owing to the complex physiological function and anatomy of the eye, Due to the many benefits this polymeric system offers, including ease of administration, decreased frequency of administration, enhanced patient compliance, and comfort, in situ gel systems have attracted a lot of

interest in recent years. One or more stimuli, such as pH change, temperature modulation, and solvent exchange, cause in situ gel formation. To ensure that the built-in nano-system can carry out the necessary activity, character them is crucial. There are several methods for character substances, including measuring pH, zeta potential, size, stability, aesthetic appeal, and other crucial ex vivo and in vivo drug delivery evaluations.[4] It provided a thorough analysis of ocular drug delivery from various angles, including the different eye anatomical features, various eye diseases, barriers to ocular delivery, various ocular administration routes, classification of dosage forms, numerous nanostructured platforms, characterization approaches, strategies to enhance ocular delivery, and future technologies. A wide range of pharmacological dosage forms, such as semisolids, liquid preparations, sprays, and solid powders, are used in topical drug delivery systems. Gels, creams, and ointments are the most popular semisolid topical drug delivery preparations. Because many of the constituents, including peptides, proteins, and chemotherapeutic drugs, would be rendered inactive if taken orally, these medications must be applied directly to the eye. The fact that preparations of all ocular dosage forms are sterile is the issue that should take precedence. A wide range of pharmacological dosage forms, such as semisolids, liquid preparations, sprays, and solid powders, are used in topical drug delivery systems.[5] Gels, creams, and ointments are the most popular semisolid topical drug delivery preparations. Because many of the constituents, including peptides, proteins, and chemotherapeutic drugs, would be rendered inactive if taken orally, these medications must be applied directly to the eye. The fact that preparations of all ocular dosage forms are sterile is the issue that should take precedence.[6] The gelling agent was sodium alginate, a new mucoadhesive polymer that forms an ocular gel when exposed to divalent cations (calcium ion) found in lachrymal fluid. An additive for viscosity is hydroxy propyl methyl cellulose (HPMC), a mucoadhesive polymer. The pH was changed to 6.5 by using buffering agents in the proper amounts. All of the formulations underwent a 15-minute autoclave at 121°C. Clarity, pH measurement, gelling ability, drug content estimation, rheological study, in vitro diffusion study, antibacterial activity, isotonicity, and ocular irritation study were all examined in relation to the formulations.[7]



Fig 1. complex physiological function and anatomy of the eye.

The eye is a round organ with a 2.5 cm diameter that is housed in the orbit of the skull, or eye socket. The outside fibrous layer, the middle vascular layer, and the inner nerve layer are its three primary layers. Outer Fibrous Layer: The cornea and the sclera make up the two primary parts of the outer fibre layer. The front surface of the eye is made up of a transparent, dome-shaped tissue called the cornea. It is essential for refracting (bending) light so that it is focused onto the retina. The sclera, which covers the back half of the eye, is a hard, white, protective coating. It supports structurally and aids in preserving the eyeball's shape.[8] Middle Vascular Layer: The iris, ciliary body, and choroid are the three components that make up the middle vascular layer, usually referred to as the uvea. The pupil, or center opening, is surrounded by the iris, the coloured portion of the eye. By changing the pupil's size, it controls how much light gets into the eye. Behind the iris is a ring-shaped structure called the ciliary body. It houses the ciliary muscle, which regulates the lens's shape and enables it to focus on things at various distances. Between the sclera and the retina, there is a layer called the choroid that is extremely vascularized. It provides the inner layers of the eye with nutrition and

oxygen. Inner Nervous Layer. The retina, which lines the back of the eye, makes up the inner nerve layer. Specialised photoreceptor cells in the retina are in charge of turning light into electrical signals that the brain can comprehend.[9]

Components of the Eye has now let's explore the key components within the eye that are involved in the process of vision. The lens is a transparent, biconvex structure supported by the ciliary body that is situated behind the iris. It is essential for directing light towards the retina. The lens can alter its shape by contracting and relaxing the ciliary muscle to change its focal length and concentrate on things at various distances. The retina is a thin, multilayered tissue that lines the back of the eye.[10] It contains millions of specialized photoreceptor cells called rods and cones. Rods are responsible for vision in low light conditions and the perception of shades of gray. Cones are responsible for color vision and high visual acuity. The retina also contains other cells, such as bipolar cells and ganglion cells, which help transmit and process visual signals. Photoreceptor Cell is the retina borders the back of the eye and is a delicate, complex tissue. It is made up of numerous millions of cones and rods, which are specialised photoreceptor cells. Low-light vision and the perception of grayscales are both mediated by rods. High eye acuity and colour perception are both attributed to cones. Bipolar and ganglion cells, among other cells found in the retina, aid in the transmission and processing of visual signals.[11] Components of the Eye: Now let's explore the key components within the eye that are involved in the process of vision. Lens: The lens is a transparent, biconvex structure supported by the ciliary body that is situated behind the iris. It is essential for directing light towards the retina. The lens can alter its shape by contracting and relaxing the ciliary muscle to change its focal length and concentrate on things at various distances. The retina borders the back of the eye and is a delicate, complex tissue. It is made up of numerous millions of cones and rods, which are specialised photoreceptor cells. Low-light vision and the perception of grayscales are both mediated by rods. High eye acuity and colour perception are both attributed to cones. Bipolar and ganglion cells, among other cells found in the retina, aid in the transmission and processing of visual signals.[12] Photoreceptor Cells: These two different types of photoreceptor cells, cones as well as rods, are found inside the retina's outer layer. Rods are more prevalent and are mostly in charge of seeing in low light. Cones, on the other hand, are concentrated in the fovea, the centre of the retinal and are in charge of colour vision. The fovea, or retina, is in charge of providing the sharpest vision. Optic Nerve: The optic nerve is a collection of nerve fibres that connects the retina to the brain and carries visual information. The optic disc, also referred to as the blind spot because it lacks photoreceptor cells, is where it leaves the eye. The photoreceptor cells' electrical signals are sent to the brain via the optic nerve.[13]

Advantages of Ophthalmic Gel

The medication delivery technology known as ophthalmic medicated gel, sometimes referred to as ophthalmic gel or ocular gel, is created exclusively for ocular uses. Its semi-solid formulation has a number of benefits over conventional eye drops and ointments. We shall go into great detail about the benefits of ocular medicated gel as a drug delivery technology in this response. Enhanced Drug Bioavailability: The capacity of ocular medicated gel to increase drug bioavailability is one of its main benefits. The longer amount of time the drug is in touch with the ocular surface thanks to the gel formulation increases drug absorption. This extended contact guarantees that more of the medicine enters the target tissues, increasing therapeutic effectiveness.[14] Extended Drug Residence Time: Because they have a thick nature, ophthalmic gels can stick to the ocular surface for a long time. By ensuring that the medicine stays in contact with the target tissues for a longer period of time, the therapeutic effect is prolonged. In contrast, tear drainage and blinking frequently cause eye drops to be quickly removed from the eye. Controlled Drug Release has a possible to develop ophthalmic gels that deliver a regulated and long-lasting medication release. The gel's rheological characteristics and composition can be changed, allowing the medication release rate to be adjusted to meet specific therapeutic requirements. This controlled release function helps keep drug concentrations within the therapeutic range for a longer period of time and reduces the need for frequent doses.[15] Improved Patient Compliance: In contrast to ointments, ophthalmic gels are often created as clear, non-blurring compositions that offer better patient acceptability and comfort. Patients are more likely to comply with treatment recommendations thanks to the convenience of administration and decreased frequency of application. This is especially advantageous for chronic illnesses that call for protracted treatment. Enhanced Ocular Surface Contact: Ophthalmic gels' gel-like nature allows them to spread uniformly throughout the ocular surface. This characteristic makes it easier for the drug to be distributed uniformly throughout the body, ensuring that it reaches the cornea, conjunctiva, and other target tissues in all areas of the eye.[15] The drug's effectiveness is increased by the large contact area, which also lowers the possibility of localised therapy failure. Protection and Lubrication: Ophthalmic gels provide a lubricating and protecting impact on the surface of the eye. They can aid in keeping tears from evaporating and maintaining ocular moisture, which will lessen dryness and discomfort. The gel matrix also serves as a barrier, shielding the eye from irritants, allergens, and pollution outside, reducing the possibility of further ocular harm. Enhanced Stability: Comparatively speaking, ophthalmic gels have better stability than other ocular formulations. The gel matrix offers a safe haven for the pharmaceuticals that have been inserted, protecting them from enzymatic, thermal, or light-induced deterioration. This improved stability increases the product's shelf life and guarantees the preservation of

pharmacological efficacy over a longer length of time.[16] Versatility in Formulation: Ophthalmic gels can hold a variety of medications, including hydrophilic and lipophilic substances. The inclusion of both lipid- and water-soluble medicines in the gel formulation increases the range of therapeutic choices. Ophthalmic gels are useful for administering a variety of pharmaceuticals, including antibiotics, anti-inflammatory drugs, lubricants, and antiglaucoma treatments, due to their formulation flexibility. Reduced Systemic Absorption: Ophthalmic gels can reduce the amount of medication that enters the system, lowering the risk of systemic side effects. The gel matrix functions as a barrier, preventing medications from entering the systemic circulation and lowering the risk of systemic toxicity. The safety profile of drugs is improved by this localised drug delivery technology, making them suitable for long-term use.[17]

Disadvantages of ophthalmic medicated gel The risk for impaired vision or other visual disturbances when using ophthalmic medicated gel, commonly known as ophthalmic gel, is one of its drawbacks. The drug's gel-like nature has the potential to leave a transient film or layer on the eye's surface, impairing vision temporarily. This may impair a person's eyesight and cause problems with activities like reading or driving that call on clear vision. The risk for eye discomfort or irritability is another drawback. When the gel is used, some people may feel stinging, burning, or irritating sensations. This may be a result of the gel's active chemicals or other formulation elements. Eye irritability can be annoying and make people less likely to follow their treatment schedule. Additionally, ophthalmic gels could function more quickly than other ophthalmic formulations like eye drops or ointments. Gels frequently dissolve from the eye or are quickly absorbed, necessitating more frequent administration to maintain therapeutic drug levels. Patients who prefer less frequent doses or have trouble applying the gel themselves may find this uncomfortable.[18] A drug delivery technique made exclusively for eye uses is ophthalmic medicated gel. Due to its distinct gel-like consistency, it has various advantages over conventional ophthalmic formulations like eye drops or ointments. Following are a few typical applications and advantages of ocular medicated gel as a drug delivery system. Drug release over an extended period of time, The gel matrix in ocular medicated gel enables a regulated, sustained release of the drug's active ingredient. This lessens the need for frequent dosing by sustaining therapeutic medication levels in the eye over an extended length of time.[19]

Mechanisms and Applications For treating eye diseases and disorders, ophthalmic medicated gels have drawn a lot of attention as efficient drug delivery vehicles. In comparison to traditional eye drops, these gel-based formulations have better bioavailability, extended drug release, increased patient compliance, and less systemic side effects. The goal of this page is to give readers a thorough grasp of the workings of ophthalmic medicated gels as drug delivery systems, as well as their makeup and potential uses in ocular therapy.[20] Gelation Mechanisms is a crucial stage in the creation of ocular medicinal gels is gelation. Gelation can be accomplished through a variety of methods, including thermal gelation, pH-induced gelation, and ion-induced gelation. While pH-induced gelation happens when the formulation comes into touch with the ocular surface and causes a change in pH, thermal gelation involves the creation of a gel matrix as a result of temperature changes. Divalent ions, like calcium or magnesium ions, are necessary for ion-induced gelation in order to crosslink the polymer chains and create a gel. Drug Release Mechanisms is Diffusion, erosion, and bioerosion are a few of the different processes by which ophthalmic gels might release medications. Drugs diffuse through the gel matrix and then enter the ocular tissues, producing diffusion-based release. Erosion-based release includes the medicine being released as the gel matrix gradually dissolves or erodes. The term "bioerosion" describes the regulated release of medication that results from the enzymatic breakdown of the gel matrix by ocular enzymes.[21]

Applications of Ophthalmic Medicated Gels Glaucoma, dry eye syndrome, conjunctivitis, and ocular infections are just a few of the ocular diseases and disorders that ophthalmic gels have been proven to be effective in treating. They are especially well suited for chronic illnesses that call for regular dosage because of their longer drug release patterns and improved ocular bioavailability. Ophthalmic gels may also be designed as in-situ gelling solutions, which gel as they come into contact with the ocular surface, making them easier to administer and increasing patient compliance. Ophthalmic gels have a number of issues that need to be resolved before they can be successfully used, despite their promising qualities. This article covers the difficulties with ocular medicated gels and offers insights on potential solutions in the future.[22]

Challenges of Ophthalmic Medicated Gels Bioavailability and Drug Release is getting the best drug bioavailability and controlled release in ocular medicated gels is one of the main challenges. Drug distribution and excretion can be impacted by the peculiar physiology of the eye, the ocular surface, and other factors. Gel formulations must minimise systemic exposure while ensuring appropriate drug release and maintaining therapeutic drug levels at the target site. Formulation Stability For ophthalmic gels to be effective and have a long shelf life, formulation stability is essential. The physical and chemical stability of these formulations is frequently compromised by issues such drug deterioration, phase separation, and gel liquefaction over time. During formulation creation, it is important to pay close attention to variables including temperature, pH, and the compatibility of active pharmaceutical ingredients (APIs) with gel matrix components. Rheological Properties Ophthalmic gels' rheological

characteristics are crucial to their use and the comfort of patients.[23] Gels must have the right viscoelasticity and viscosity for simple administration and for effective spreading and retention on the ocular surface. It might be difficult to achieve the necessary rheological properties since it needs balancing elements including gel strength, cohesiveness, and shear thinning behaviour. Preocular Residence Time Increasing the residence period of ophthalmic gels on the ocular surface is a substantial obstacle. Traditional eye drops have a limited residence time, which limits drug absorption and necessitates frequent dosing, which decreases patient compliance. To get around this restriction, ophthalmic gels should stick to the ocular surface, withstand tear dilution, and offer prolonged drug release. Sterility and Microbial Contamination To reduce the danger of contamination and infection, ophthalmic gels must be sterile. Sterility control is important yet difficult during production, storage, and administration. Gels should be created, stored, and administered in a way that reduces the possibility of microbial growth and guarantees patient security.[24]

Medicated gel formulation Excipients play important roles in ophthalmic medicated gel formulations by assisting in the stability, viscosity, bioavailability, and overall effectiveness of the product. Here are the roles of some Gelling agents: These excipients are responsible for providing the gel-like consistency to the formulation. They increase the viscosity and provide a suitable texture for application.[25] Examples include carbomers (e.g., Carbopol), cellulose derivatives (e.g., hydroxypropyl methylcellulose), and gelatin. Preservatives: Ophthalmic formulations are susceptible to microbial contamination due to their contact with the eyes. Preservatives help prevent the growth of microorganisms and maintain the sterility of the product. Commonly used preservatives include benzalkonium chloride, chlorobutanol, and polyquaternium compounds.[23] Viscosity modifiers: These excipients control the viscosity and rheological properties of the gel formulation, ensuring proper spread ability, ease of application, and retention on the ocular surface. Viscosity modifiers include various polymers such as hydroxypropyl methylcellulose, polyvinyl alcohol, and polyethylene glycol. Buffering agents: Ophthalmic medicated gels often require a specific pH range to maintain stability and compatibility with the ocular tissues. Buffering agents help maintain the desired pH by resisting changes in acidity or alkalinity. Common buffering agents include sodium phosphate, citric acid, and borate buffers.[26] Osmotic agents: These excipients help to maintain the tonicity of the formulation, ensuring that it is isotonic with the ocular tissues. Osmotic agents, such as sodium chloride or mannitol, help prevent discomfort or irritation to the eyes caused by a significant difference in tonicity. Chelating agents: Chelating agents are used to enhance the stability and prevent the degradation of active pharmaceutical ingredients (APIs) by chelating or binding metal ions that can catalyze degradation reactions. Examples of chelating agents used in ophthalmic formulations include ethylenediaminetetraacetic acid (EDTA) and citric acid.[27] Stabilizers: Stabilizers are used to enhance the physical and chemical stability of the formulation, preventing degradation or loss of activity of the active ingredients. Common stabilizers used in ophthalmic gels include antioxidants (e.g., sodium metabisulfite, ascorbic acid) and surfactants (e.g., polysorbate 80, Tween 80). Ocular penetration enhancers: Some ophthalmic gels may contain excipients that enhance the penetration of the active ingredients into the ocular tissues, thereby improving the bioavailability and therapeutic efficacy. Examples of ocular penetration enhancers include cyclodextrins, surfactants, and lipid-based excipients. It's important to note that the specific excipients used in ophthalmic medicated gel formulations can vary depending on the intended purpose of the formulation, the active ingredients involved, and other formulation considerations.[28]

Commonly used substances in each category In medicated ophthalmic gels, there are various geling agents, viscosity modifiers, and preservatives used to enhance the formulation's stability, viscosity, and shelf life. Here are some examples: Gelling Agents: Carbomer: Examples include Carbomer 940, Carbomer 980, and Carbomer 934. They are synthetic high-molecular-weight polymers that create a gel-like consistency when dispersed in water or other solvents.[29] Hydroxyethyl cellulose (HEC): It is a cellulose-derived polymer that forms a gel when hydrated. It is often used in combination with other gelling agents. Sodium carboxymethylcellulose (Na CMC): This cellulose derivative acts as a thickening and gelling agent in ophthalmic gels. Viscosity Modifiers: Polyethylene glycol (PEG): It is a water-soluble polymer that can increase the viscosity of ophthalmic gels. Poloxamer: Examples include Poloxamer 407 and Poloxamer 188. These nonionic surfactants can provide viscosity and enhance the gel's lubricating properties. Methylcellulose: It is a cellulose derivative used to increase the viscosity of ophthalmic gels. Preservatives: Benzalkonium chloride (BAK): It is a common preservative used in ophthalmic formulations to prevent microbial growth. BAK has broad-spectrum antimicrobial activity.[30] Polyquaternium-1 (Polyquad): It is a preservative that exhibits antimicrobial properties and is often used as an alternative to BAK. Chlorobutanol: This preservative has antimicrobial properties and is commonly used in ophthalmic formulations. Please note that the specific choice and concentration of these agents may vary depending on the formulation requirements and regulatory guidelines. It is important to consult the specific product's packaging or a healthcare professional for accurate and up-to-date information Chelating Agents: Ethylenediaminetetraacetic acid (EDTA) Disodium ethylenediaminetetraacetic acid (Disodium EDTA) Citric acid Stabilizing Agents: Hydroxypropyl methylcellulose (HPMC)Carbomer Polyvinyl alcohol (PVA) Polyvinylpyrrolidone (PVP) Osmotic Agents:

Sodium chloride Glycerin Mannitol Ophthalmic Stabilizing Agents: Sodium hyaluronate Polyethylene glycol (PEG) Propylene glycol.[31]

The mechanism of action of ophthalmic medicated gel formulations involves several key aspects: Ophthalmic medicated gel formulations are specialized formulations designed for ocular application. These gels are formulated to deliver therapeutic agents, such as drugs or lubricants, to the eye for the treatment of various eye conditions. Gel Matrix: The gel matrix serves as the vehicle for delivering the active ingredients to the eye.[32] It is typically composed of a polymer network that provides the required physical properties, such as viscosity and mucoadhesive properties, necessary for optimal ocular application. The gel matrix acts as a reservoir, gradually releasing the active ingredients over time. Drug Release: Ophthalmic gels are designed to release the active ingredients in a controlled manner. This release can be achieved through various mechanisms, such as diffusion, erosion, or a combination of both. The gel matrix controls the rate at which the drug is released, ensuring a sustained therapeutic effect.[33] Mucoadhesion: Ophthalmic gels often possess mucoadhesive properties, allowing them to adhere to the ocular surface, such as the cornea or conjunctiva. This mucoadhesive nature helps prolong the contact time of the gel with the eye, facilitating better drug absorption and efficacy. Drug Penetration: The gel formulation should allow for efficient penetration of the active ingredients into the ocular tissues. The gel matrix should have the appropriate rheological properties to ensure that the drug can penetrate the corneal epithelium and reach the target site of action within the eye.[34] Stability: Ophthalmic gels need to maintain stability over the course of their shelf life and during application. They should retain their physical properties, drug release characteristics, and sterility to ensure consistent and reliable treatment. It's important to note that the specific mechanism of action can vary depending on the particular formulation, active ingredient, and desired therapeutic outcome. The development of ophthalmic medicated gel formulations involves careful consideration of factors such as drug solubility, viscosity, biocompatibility, and patient comfort to optimize the effectiveness of the treatment.[35]

Roles of the gel matrix in ophthalmic medicated gels: The gel matrix used in ophthalmic medicated gels plays a crucial role in the formulation and delivery of drugs to the eye. It serves as a vehicle for the active pharmaceutical ingredient (API) and provides a controlled release of the medication onto the ocular surface. Drug encapsulation: The gel matrix acts as a three-dimensional network that encapsulates the drug molecules, keeping them in a stable and dispersed form within the gel. This ensures uniform distribution and prevents drug precipitation or aggregation.[36] Viscosity and stability: The gel matrix imparts viscosity to the formulation, giving it a semi-solid consistency. This allows the gel to adhere to the ocular surface, providing prolonged contact time for drug absorption. The gel matrix also helps maintain the stability of the medication by preventing degradation or evaporation. Controlled release: The gel matrix controls the release of the drug over time. The gel may be designed to release the medication slowly and steadily, extending the therapeutic effect and reducing the need for frequent application. This controlled release mechanism is often important for sustained drug delivery to the eye.[37] Enhanced bioavailability: The gel matrix can enhance the bioavailability of the drug by increasing its retention time on the ocular surface. This allows for better absorption through the cornea or conjunctiva, leading to improved therapeutic outcomes. Comfort and ease of application: Ophthalmic gels formulated with a suitable gel matrix often provide comfort to the patient during application. The gel's consistency allows for easy spreading and reduced irritation compared to other dosage forms such as solutions or ointments. The selection of the gel matrix depends on various factors, including the desired release profile, compatibility with the drug, and biocompatibility with the ocular tissues. Common gel matrices used in ophthalmic formulations include hydrogels, cellulose derivatives (such as methylcellulose or hydroxyethyl cellulose), and carbomer-based gels. It's important to note that specific formulations and gel matrices may vary depending on the intended use and the specific drug being incorporated into the ophthalmic gel.[38]

Drug Release Mechanisms of Ophthalmic Medicated Gel Formulations Ophthalmic medicated gel formulations have gained significant attention as effective drug delivery systems for the treatment of ocular disorders. These gels provide sustained drug release, enhancing therapeutic efficacy and patient compliance. This article explores the drug release mechanisms involved in ophthalmic medicated gel formulations.[39] It covers the physicochemical properties of gels, formulation factors affecting drug release, and various mechanisms governing drug release from the gel matrix. A comprehensive understanding of these mechanisms is crucial for the development of optimized gel formulations for ocular drug delivery. Ophthalmic diseases, including glaucoma, dry eye syndrome, and bacterial or viral infections, require localized drug delivery to the ocular tissues. Medicated gels offer several advantages over traditional ophthalmic dosage forms, such as eye drops or ointments, due to their ability to provide sustained release and improved ocular bioavailability.[40] The drug release mechanisms in these gel formulations play a vital role in achieving therapeutic outcomes. Physicochemical Properties of Ophthalmic Medicated Gels: The drug release mechanism in ophthalmic gels depends on their physicochemical properties, including gel type, rheological behavior, gelation process, and gel microstructure. Different gelling agents, such as natural polymers (e.g., cellulose derivatives, chitosan, hyaluronic acid) or synthetic

polymers (e.g., polyvinyl alcohol, polyethylene glycol), affect the gel matrix and ultimately influence drug release kinetics. Formulation Factors Influencing Drug Release: Several formulation factors impact the drug release from ophthalmic medicated gels. These factors include drug solubility, drug loading, drug-polymer interactions, pH, osmolarity, and viscosity of the gel. Proper optimization of these factors is essential to achieve controlled and sustained drug release. Diffusion-Based Drug Release Mechanisms: Diffusion plays a significant role in drug release from ophthalmic gels. Fick's law of diffusion governs the drug release process, where the drug molecules diffuse through the gel matrix, driven by a concentration gradient.[41] Factors affecting diffusion-based release include drug molecular weight, diffusivity, concentration gradient, and gel porosity. Swelling-Controlled Drug Release Mechanisms: Swelling-controlled drug release occurs when the gel matrix absorbs fluid from the ocular environment, leading to gel expansion and subsequent drug release. Swelling is influenced by gel composition, polymer hydrophilicity, cross-linking density, and osmotic pressure. The degree of swelling directly affects drug release kinetics.[5] Matrix Erosion-Controlled Drug Release Mechanisms: In matrix erosion-controlled drug release, the gel matrix undergoes erosion, resulting in the release of drug molecules. Erosion occurs due to the dissolution, degradation, or enzymatic breakdown of gel matrix components. Factors such as gel composition, polymer degradation rate, and environmental conditions affect erosion-based drug release.[5] Ion-Exchange Controlled Drug Release Mechanisms: Certain ophthalmic gels employ ion-exchange mechanisms for drug release.[42] The presence of ionizable groups in the gel matrix enables the exchange of ions with the ocular environment, facilitating controlled drug release. Parameters affecting ion-exchange-based release include gel composition, ion concentration gradient, pH, and ionic strength. Combination Drug Release Mechanisms In many cases, drug release from ophthalmic gels involves a combination of diffusion, swelling, erosion, and ion-exchange mechanisms. The interplay between these mechanisms depends on the gel formulation, drug properties, and environmental factors. Understanding these interactions is crucial for optimizing drug release profiles.[43]

In Vitro and In Vivo Evaluation of Drug Release

Ophthalmic drug delivery plays a crucial role in the treatment of various ocular diseases. The development of effective drug delivery systems, such as medicated gel formulations, has gained significant attention in recent years. This study aims to evaluate the in vitro and in vivo characteristics of an ophthalmic medicated gel formulation. The formulation's physicochemical properties, drug release behavior, and ocular tolerability will be assessed to determine its potential for ocular drug delivery.[44] Ocular drug delivery poses several challenges due to the unique anatomy and physiology of the eye. Traditional dosage forms, such as eye drops, have limitations in terms of poor bioavailability and short residence time on the ocular surface. Medicated gel formulations offer advantages over conventional dosage forms, including prolonged drug release, increased contact time, and improved patient compliance. This study aims to investigate the in vitro and in vivo characteristics of an ophthalmic medicated gel formulation, including physicochemical properties, drug release behavior, and ocular tolerability.[45]

Methodology: Formulation Development: The ophthalmic medicated gel formulation will be developed using a suitable polymer matrix and drug. The formulation will be optimized to achieve desirable rheological properties and drug release characteristics. Physicochemical Characterization: The physicochemical properties of the formulated gel, including pH, viscosity, gelation temperature, and drug content, will be determined.[46] These parameters are crucial for ensuring stability and suitability for ocular administration. In Vitro Drug Release Studies: The drug release profile of the formulated gel will be evaluated using in vitro release studies. The gel will be placed in a suitable membrane or diffusion cell setup, and the drug release will be monitored over time. Various factors such as gel composition, drug concentration, and release media will be investigated to optimize the drug release behavior. Ocular Irritation and Tolerance To assess the ocular tolerability of the medicated gel, in vitro and in vivo ocular irritation studies will be conducted. In vitro cytotoxicity assays using corneal epithelial cell lines will be performed. Additionally, an in vivo rabbit eye irritation study will be conducted, following internationally accepted guidelines.[47] In Vivo Drug Pharmacokinetics: To evaluate the drug absorption and pharmacokinetics, in vivo studies will be performed using an animal model (e.g., rabbits). The formulated gel will be topically administered, and the drug concentration in the ocular tissues and aqueous humor will be determined at various time points. This data will provide insights into the drug's bioavailability and distribution within the eye. Physicochemical Characterization: The physicochemical properties of the formulated gel, including pH, viscosity, gelation temperature, and drug content, will be presented and discussed. Any observed changes in these properties over time will be noted, indicating the formulation's stability. In Vitro Drug Release Studies: The drug release profiles of the medicated gel under different experimental conditions will be presented and analyzed. The impact of gel composition, drug concentration, and release media on drug release behavior will be discussed.[48] Ocular Irritation and Tolerance: The results of the in vitro cytotoxicity assays and in vivo rabbit eye irritation studies will be discussed to evaluate the ocular tolerability of the gel formulation. Any observed adverse effects or signs of irritation will be reported. In Vivo Drug Pharmacokinetics: The pharmacokinetic profiles of the drug in ocular tissues and aqueous humor following topical administration of the gel will be presented and

discussed.[49] The data will provide insights into the drug's Ophthalmic medicated gel formulations are designed to deliver drugs to the eye for the treatment of various ocular conditions. Compared to eye drops, gels offer distinct advantages, including prolonged drug residence time, improved drug bioavailability, reduced systemic absorption, and ease of application. However, the comfort and stability of these formulations play crucial roles in their success. This review delves into the factors influencing comfort and stability, highlighting their importance in ophthalmic gel formulation development.[50]

Comfort of Ophthalmic Medicated Gels Viscosity and Rheology The viscosity and rheological properties of ophthalmic gels significantly impact their comfort. Gels with appropriate viscosity provide good spread ability and ease of application, ensuring patient comfort during administration. Rheological parameters, such as shear-thinning behavior and gel strength, are vital for optimal gel performance and patient satisfaction. Transparency and Clarity Transparency and clarity are desirable attributes for ophthalmic gels.[51] Clear gels enhance patient acceptance by minimizing blurred vision and foreign body sensation. Formulation strategies to achieve transparency, such as proper selection of excipients, elimination of particulate matter, and prevention of phase separation, are discussed in this section. pH and Osmolality The pH and osmolality of ophthalmic gels are critical determinants of ocular comfort. Maintaining the physiological pH and osmolality range of the eye is essential to prevent stinging, burning, or irritation upon gel application. This section explores the impact of pH modifiers and osmotic agents on the comfort of ophthalmic gels.[52] Non-Irritating Preservatives Preservatives are incorporated into ophthalmic gels to prevent microbial contamination. However, the choice of preservative is crucial to avoid ocular irritation or toxicity. This section discusses non-irritating preservatives commonly used in ophthalmic gels, their mechanisms of action, and their impact on patient comfort.[53]

Stability of Ophthalmic Medicated Gels Chemical Stability Chemical stability refers to the ability of an ophthalmic gel to maintain its active pharmaceutical ingredient(s) (API) in a stable state over time. Factors affecting chemical stability, such as drug degradation pathways, pH effects, and antioxidant systems, are explored in detail. Additionally, strategies to enhance chemical stability, including formulation optimization, packaging considerations, and the use of stabilizing agents, are discussed.[54] Physical Stability Physical stability encompasses various aspects, including gel appearance, homogeneity, and phase separation. Gels should maintain their physical characteristics throughout their shelf life, ensuring consistent drug delivery and ease of administration. This section examines factors influencing physical stability, such as gel microstructure, particle size, and compatibility between drug and excipients. Microbial Stability Microbial stability is critical to prevent ocular infections caused by contaminated ophthalmic gels.[55] This section discusses the importance of microbial stability testing, the selection of appropriate antimicrobial agents, and the role of preservatives in maintaining microbial stability Ophthalmic medicated gel formulations have gained significant attention in recent years due to their numerous advantages over traditional ophthalmic formulations, such as eye drops and ointments. This review aims to explore the aspects of comfort and stability of ophthalmic medicated gel formulations in detail.[56]

Opthalmic Gel drug release factors The formulation factors play a crucial role in determining the drug release mechanism in ophthalmic medicated gels. These factors influence various aspects of gel formulation, such as drug solubility, gel viscosity, gel structure, and drug diffusion through the gel matrix. Understanding and optimizing these formulation factors are essential for achieving desired drug release kinetics and therapeutic efficacy. In this article, we will discuss the key formulation factors influencing the drug release mechanism in ophthalmic medicated gels. Polymer Selection: The choice of polymer is critical in ophthalmic gel formulation as it determines the gel's physical and chemical properties.[57] Polymers like hydroxypropyl methylcellulose (HPMC), polyvinyl alcohol (PVA), and carbomer are commonly used in ophthalmic gels due to their excellent mucoadhesive properties. The polymer's molecular weight and concentration significantly impact the gel viscosity and drug release rate. Higher polymer concentrations and higher molecular weights generally result in slower drug release rates. Drug Solubility: The drug's solubility in the gel matrix affects its release mechanism. Hydrophilic drugs tend to release more quickly from gels compared to hydrophobic drugs. The drug's solubility determines its diffusion through the gel matrix, and drugs with high solubility will have faster release rates. Formulation strategies such as co-solvents or complexation techniques can be employed to improve drug solubility and control the release rate.[58] Gel Viscosity: The viscosity of the ophthalmic gel affects drug diffusion and release. Higher gel viscosity slows down drug release due to increased resistance to drug diffusion. The gel viscosity can be controlled by adjusting the polymer concentration, molecular weight, and crosslinking density. It is important to strike a balance between gel viscosity and patient comfort, as excessively viscous gels may cause discomfort upon administration. Gel Structure: The gel structure is influenced by factors such as polymer crosslinking and gelation mechanism. Crosslinking agents like polyethylene glycol (PEG) or calcium ions can be added to the gel formulation to enhance gel stability and control drug release. The gel structure affects drug diffusion paths within the matrix, and a more open structure allows faster drug release compared to a dense structure. pH and Ionic Strength:

The pH and ionic strength of the gel formulation can affect drug release.[59] Changes in pH can alter the polymer's solubility or gelation properties, impacting drug diffusion and release. Additionally, the presence of ions can influence the electrostatic interactions between the drug and the gel matrix, affecting drug release kinetics. These factors need to be considered when formulating ophthalmic gels for specific drug release profiles. Drug Loading and Particle Size: The drug loading capacity and particle size distribution within the gel matrix influence drug release kinetics. Higher drug loading can result in a burst release at the initial stage, followed by sustained release. The particle size of the drug can also affect its diffusion through the gel matrix, with smaller particles exhibiting faster release rates. Optimization of drug loading and particle size distribution is crucial to achieve the desired release profile. Co-solvents and Penetration Enhancers: The addition of co-solvents or penetration enhancers can modulate drug release from ophthalmic gels. Co-solvents like propylene glycol or ethanol can increase drug solubility, leading to faster release rates. Penetration enhancers can improve drug permeation across the cornea and enhance drug bioavailability. These additives should be carefully chosen to ensure compatibility with the ocular tissues and to avoid irritation or adverse effects. Preservatives and Antioxidants: Ophthalmic gels often require the inclusion of preservatives and antioxidants to maintain sterility and stability.[60]

Polymer Selection for Ophthalmic Gel

When selecting a polymer for ophthalmic medicated gel, there are several factors to consider, including the gel's desired properties, compatibility with the active pharmaceutical ingredient (API), biocompatibility, stability, and ease of formulation. Here are some commonly used polymers in ophthalmic gels[61] Carbomers: Carbomers, such as carbomer 940 or carbomer 980, are widely used in ophthalmic gels. They provide good viscosity, mucoadhesive properties, and long-lasting residence time on the ocular surface.[33] Carbomers can be neutralized to form a gel and are compatible with a wide range of APIs. Hydroxypropyl methylcellulose (HPMC): HPMC is a cellulose derivative that forms transparent gels. It provides excellent viscosity control, lubrication, and ocular surface protection. HPMC-based gels are often used in artificial tears and lubricant eye drops due to their biocompatibility. Poloxamers: Poloxamers, such as Poloxamer 407, are block copolymers that exhibit both gel-like and liquid properties.[62] They can form thermos reversible gels, meaning they become gel-like at lower temperatures and liquid-like at higher temperatures. Poloxamers are frequently used in ophthalmic formulations because of their good solubilizing properties and ease of gelation. Polyvinyl alcohol (PVA): PVA is a water-soluble polymer that can form transparent gels.[34] It has excellent mucoadhesive properties and can provide sustained release of drugs. PVA-based gels are often used in ophthalmic drug delivery systems. Polyethylene glycol (PEG): PEG is a biocompatible polymer that can form gels with high water content. It provides lubrication and prolonged residence time on the ocular surface.[63] PEG-based gels are commonly used in artificial tears and ocular lubricants. It's important to note that the selection of a specific polymer will depend on the specific requirements of your ophthalmic gel formulation, including the API, desired rheological properties, and intended therapeutic effect. Conducting compatibility studies and consulting with a formulation scientist or pharmacist experienced in ophthalmic formulations can help guide the selection process.[64]

Future Perspectives Advanced Drug Delivery Systems The creation of sophisticated drug delivery methods has the potential to significantly enhance ophthalmic gel compositions. Systems based on nanotechnology, like nanogels, liposomes, and nanoparticles, can improve medication penetration and targeting, enhancing bioavailability and therapeutic results. Additionally, these systems have the ability to deliver continuous drug release, extending the time of action and lowering dosage requirements.[24] Bioengineered Gels Natural polymers and biomaterials are incorporated into bioengineered gels, opening up new possibilities for ocular medicine. These gels can improve biocompatibility, stimulate tissue regeneration, and imitate the natural ocular environment. Bioengineered gels may enable tissue repair and regeneration by integrating growth factors or stem cells into the gel matrix, revolutionising the treatment of eye illnesses. Multifunctional Gels Future ophthalmic gels may integrate multiple functions, such as drug delivery, lubrication, and ocular protection.

CONCLUSION

These gum-based in situ gelling technologies could be an excellent replacement for existing systems. The aforementioned analysis led to the conclusion that the majority of in-process and final manufacturing quality tests in IP, BP, and USP include eye preparations. However, certain discrepancies were noted, such as the fact that some tests are included in just one pharmacopoeia. Some tests described in various pharmacopoeias have varying limits that must be met. The variations in these tests and limits specifications, however, need to be streamlined and harmonized so that if the test limits meet the harmonized limits, it must also meet all pharmacopeial and regulatory requirements of that specific country. There must be equivalent novelties related with the drug candidates by comprehending the limits of ocular drug nature, eye physiology, and disease situations. To maximized the medication delivery to deeper ocular tissue, the qualities of drug candidates such as instability and poor water solubility must be enhanced. Therefore, if we take into account the physiology and features of the anterior and posterior barriers for their nature and structure, the conventional strategy to treating ocular diseases needs to be modified. Because they have a shorter precorneal residence duration, traditional ocular solutions, for example, cannot provide the necessary

release profiles. Implants, on the other hand, can provide a sustained release but are limited in terms of patient compliance because they are an invasive procedure.

REFERANCES

1. G. Jacobs, M. Martens, J.D. Beer, Selecting Optimal Dosage Volumes for Eye Irritation Tests in The Rabbit, Cut. & Ocular Toxicol, 1987; 6: 109-116.
2. B. Srividya, R.M. Cardoza, P. Amin, Sustained ophthalmic delivery of ofloxacin from a pH triggered in situ gelling system, Journal of controlled release, 2001; 73: 205-211.
3. B. Jeong, S.W. Kim, Y.H. Bae, Thermosensitive sol–gel reversible hydrogels, Advanced drug delivery reviews, 2012; 64: 154-162.
4. S. Cohen, E. Lobel, A. Trevgoda, Y. Peled, A novel in situ-forming ophthalmic drug delivery system from alginates undergoing gelation in the eye, Journal of controlled release, 1997; 44: 201-208.
5. V.H. Lee, J.R. Robinson, Mechanistic and quantitative evaluation of precorneal pilocarpine disposition in albino rabbits, J Pharm Sci., 1979; 68: 673-684.
6. R.D. Bachu, P. Chowdhury, Z.H. Al-Saedi, P.K. Karla, S.H. Boddu, Ocular drug delivery barriers—role of nanocarriers in the treatment of anterior segment ocular diseases, Pharmaceutics, 2018; 10: 28.
7. K. Jtirvinena, T. Javinen, A. Urttia, Ocular absorption following topical delivery, Ad. Drug Del. Reviews, 1995; 16: 39-43.
8. T.F. Patton, J.R. Robinson, Quantitative precorneal disposition of topically applied pilocarpine nitrate in rabbit eyes, J Pharm Sci., 1976; 65: 1295-1301.
9. Y.C. Kim, B. Chiang, X. Wu, M.R. Prausnitz, Ocular delivery of macromolecules, Journal of Controlled Release, 2014; 190: 172-181.
10. R. Gaudana, H.K. Ananthula, A. Parenky, A.K. Mitra, Ocular drug delivery, The AAPS journal, 2010; 12: 348-360. [39] R.D. Schoenwald, H.S. Huang, Corneal penetration behavior of β-blocking agents I: Physicochemical factors, Journal of pharmaceutical sciences, 1983; 72: 1266-1272.
11. M. Barsotti, S. Bartels, T. Freddo, R. Kamm, The source of protein in the aqueous humor of the normal monkey eye, Investigative ophthalmology & visual science, 1992; 33: 581-595.
12. J.M. Conrad, J.R. Robinson, Aqueous chamber drug distribution volume measurement in rabbits, Journal of pharmaceutical sciences, 1977; 66: 219-224.
13. R.D. Schoenwald, Ocular pharmacokinetics and pharmacodynamics, in: Ophthalmic drug delivery systems, CRC Press, 2003; 156-201.
14. S. Duvvuri, S. Majumdar, A.K. Mitra, Drug delivery to the retina: challenges and opportunities, Expert opinion on biological therapy, 2003; 3: 45-56.
15. A. Bochot, P. Couvreur, E. Fattal, Intravitreal administration of antisense oligonucleotides: potential of liposomal delivery, Progress in retinal and eye research, 2000; 19: 131-147.
16. Y. Ge, A. Zhang, R. Sun, J. Xu, T. Yin, H. He, J. Gou, J. Kong, Y. Zhang, X. Tang, Penetratin modified lutein nanoemulsion in-situ gel for the treatment of age-related macular degeneration, Expert Opinion on Drug Delivery, (2020).
17. E.B. Souto, J. Dias-Ferreira, A. López-Machado, M. Ettcheto, A. Cano, A. Camins Espuny, M. Espina, M.L. Garcia, E. Sánchez-López, Advanced formulation approaches for ocular drug delivery: state-of-the-art and recent patents, Pharmaceutics, 2019; 11: 460.
18. R. Suri, S. Beg, K. Kohli, Target strategies for drug delivery bypassing ocular barriers, Journal of Drug Delivery Science and Technology, 2020; 55: 101389.
19. M.J. Newton, Impact of ocular compatible Lipoids and Castor oil in fabrication of brimonidine tartrate nanoemulsions by 33 full factorial design, Recent patents on inflammation & allergy drug discovery, 2018; 12: 169-183.
20. A. Gupta, Nanoemulsions, in: Nanoparticles for Biomedical Applications, Elsevier, 2020; 371-384. [50] Y. Singh, J.G. Meher, K. Raval, F.A. Khan, M. Chaurasia, N.K. Jain, M.K. Chourasia, Nanoemulsion: Concepts, development and applications in drug delivery, Journal of controlled release, 2017; 252: 28-49.
21. R.A. Hitchings, R.J. Smith, Experience with pilocarpine Ocuserts, Trans Ophthalmol Soc U K., 1977; 97: 202-205.
22. G.K. Krieglstein, Pilocarpine-ocusert-p-40 in the handicapped glaucoma patient (author's transl), Klin Monbl Augenheilkd., 1975; 167: 55-61.
23. V.B. Patravale, A.A. Date, R.M. Kulkarni, Nanosuspensions: a promising drug delivery strategy, J Pharm Pharmacol., 2004; 56: 827-840. [54] S.M. Agnihotri, P.R. Vavia, Diclofenac-loaded biopolymeric nanosuspensions for ophthalmic application, Nanomedicine., 2009; 5: 90-95. Epub 2008 Sep 2026.
24. E. Barbu, L. Verestiuc, M. Iancu, A. Jatariu, A. Lungu, J. Tsibouklis, Hybrid polymeric hydrogels for ocular drug delivery: nanoparticulate systems from copolymers of acrylic acid-functionalized chitosan and N-isopropylacrylamide or 2-hydroxyethyl methacrylate, Nanotechnology., 2009; 20: 225108. Epub 222009 May 225112.
25. Kesarla, Rajesh, Tanvi Tank, Pratik Ashwinbhai Vora, Tanvi Shah, Sagar Parmar, and Abdelwahab Omri. "Preparation and evaluation of nanoparticles loaded ophthalmic in situ gel." Drug delivery 23, no. 2016; 7: 2363-2370.
26. Jelvehgari, Mitra, and Hassan Montazam. "Evaluation of mechanical and rheological properties of metronidazole gel as local delivery system." Archives of pharmacal research, 2011; 34(6): 931-940.
27. J. Han, K. Wang, D. Yang, J. Nie, Photopolymerization of methacrylated chitosan/PNIPAAm hybrid dual-sensitive hydrogels as carrier for drug delivery, Int J Biol Macromol.,

2009; 44: 229-235. Epub 2008 Dec 2025. Journal Pre-proof Journal Pre-proof 53 [57] G. Abdelbary, Ocular ciprofloxacin hydrochloride mucoadhesive chitosan-coated liposomes, (2009). s

28. Kaur, Indu Pal, and R. Smitha. "Penetration enhancers and ocular bioadhesives: two new avenues for ophthalmic drug delivery." Drug development and industrial pharmacy, 2002; 28(4): 353-369.
29. Chellathurai, Benedict Jose, Ramyadevi Anburose, Mohammad H. Alyami, Mohan Sellappan, Mohammad F. Bayan, Balakumar Chandrasekaran, Kumarappan Chidambaram, and Mohamed Rahamathulla. "Development of a Polyherbal Topical Gel for the Treatment of Acne." Gels, 2023; 9(2): 163.
30. Kar, Mousumi, Yashu Chourasiya, Rahul Maheshwari, and Rakesh K. Tekade. "Current developments in excipient science: implication of quantitative selection of each excipient in product development." In Basic fundamentals of drug delivery, pp. 29-83. Academic Press, 2019.
31. de la Fuente, Maria, Manuela Raviña, Patrizia Paolicelli, Alejandro Sanchez, Begoña Seijo, and Maria Jose Alonso. "Chitosan-based nanostructures: a delivery platform for ocular therapeutics." Advanced drug delivery reviews, 2010; 62(1): 100-117.
32. Vinardell, M. P., and M. Mitjans. "Alternative methods for eye and skin irritation tests: an overview." Journal of pharmaceutical sciences, 2008; 97(1): 46-59.
33. Vasvani, Shyam, Pratik Kulkarni, and Deepak Rawtani. "Hyaluronic acid: A review on its biology, aspects of drug delivery, route of administrations and a special emphasis on its approved marketed products and recent clinical studies." International journal of biological macromolecules, 2020; 151: 1012-1029.
34. Achouri, Djamila, Kamel Alhanout, Philippe Piccerelle, and Véronique Andrieu. "Recent advances in ocular drug delivery." Drug development and industrial pharmacy, 2013; 39(11): 1599-1617.
35. Choonara, Yahya E., Viness Pillay, Michael P. Danckwerts, Trevor R. Carmichael, and Lisa C. Du Toit. "A review of implantable intravitreal drug delivery technologies for the treatment of posterior segment eye diseases." Journal of pharmaceutical sciences, 2010; 99(5): 2219-2239.
36. Annaka, Masahiko, Kell Mortensen, Toyoaki Matsuura, Masaya Ito, Katsunori Nochioka, and Nahoko Ogata. "Organic–inorganic nanocomposite gels as an in situ gelation biomaterial for injectable accommodative intraocular lens." Soft Matter, 2012; 8(27): 7185-7196.
37. Lindsey, William H., Roy C. Ogle, Raymond F. Morgan, Robert W. Cantrell, and Thomas M. Sweeney. "Nasal reconstruction using an osteoconductive collagen gel matrix." Archives of Otolaryngology–Head & Neck Surgery, 1996; 122(1): 37-40.
38. Kobayashi, T., Kim, H., Liu, X., Sugiura, H., Kohyama, T., Fang, Q., Wen, F.Q., Abe, S., Wang, X., Atkinson, J.J. and Shipley, J.M., 2014. Matrix metalloproteinase-9 activates TGF-β and stimulates fibroblast contraction of collagen gels. American Journal of Physiology-Lung Cellular and Molecular Physiology, 306(11): L1006-L1015.
39. Al-Kinani, Ali A., Ghada Zidan, Naba Elsaid, Ali Seyfoddin, Adam WG Alani, and Raid G. Alany. "Ophthalmic gels: Past, present and future." Advanced drug delivery reviews, 2018; 126: 113-126.
40. Cooper, Remy C., and Hu Yang. "Hydrogel-based ocular drug delivery systems: Emerging fabrication strategies, applications, and bench-to-bedside manufacturing considerations." Journal of Controlled Release, 2019; 306: 29-39.
41. Hao, Jifu, Xiaodan Wang, Yanping Bi, Yufang Teng, Jianzhu Wang, Fei Li, Qiankui Li, Jimei Zhang, Fengguang Guo, and Jiyong Liu. "Fabrication of a composite system combining solid lipid nanoparticles and thermosensitive hydrogel for challenging ophthalmic drug delivery." Colloids and Surfaces B: Biointerfaces, 2014; 114: 111-120.
42. Agrawal, Ashish Kumar, Manasmita Das, and Sanyog Jain. "In situ gel systems as 'smart'carriers for sustained ocular drug delivery." Expert opinion on drug delivery, 2012; 9(4): 383-402.
43. Grassiri, Brunella, Ylenia Zambito, and Andreas Bernkop-Schnürch. "Strategies to prolong the residence time of drug delivery systems on ocular surface." Advances in colloid and interface science, 2021; 288: 102342.
44. El-Kamel, A. H. "In vitro and in vivo evaluation of Pluronic F127-based ocular delivery system for timolol maleate." International journal of pharmaceutics, 2002; 241(1): 47-55.
45. Maulvi, Furqan A., Dhara H. Lakdawala, Anjum A. Shaikh, Ankita R. Desai, Harsh H. Choksi, Rutvi J. Vaidya, Ketan M. Ranch, Akshay R. Koli, Bhavin A. Vyas, and Dinesh O. Shah. "In vitro and in vivo evaluation of novel implantation technology in hydrogel contact lenses for controlled drug delivery." Journal of Controlled Release, 2016; 226: 47-56.
46. Jain, Pooja, Chandra Prakash Jaiswal, Mohd Aamir Mirza, Md Khalid Anwer, and Zeenat Iqbal. "Preparation of levofloxacin loaded in situ gel for sustained ocular delivery: in vitro and ex vivo evaluations." Drug development and industrial pharmacy, 2020; 46(1): 50-56.
47. Franca, Jucara Ribeiro, Giselle Foureaux, Leonardo Lima Fuscaldi, Tatiana Gomes Ribeiro, Livia Bomfim Rodrigues, Renata Bravo, Rachel Oliveira Castilho et al. "Bimatoprost-loaded ocular inserts as sustained release drug delivery systems for glaucoma treatment: in vitro and in vivo evaluation." PloS one, 2014; 9(4): e95461.

48. Rafie, Farzaneh, Yousef Javadzadeh, Ali R. Javadzadeh, Leila Alizadeh Ghavidel, Behzad Jafari, Mohammad Moogooee, and Soodabeh Davaran. "In vivo evaluation of novel nanoparticles containing dexamethasone for ocular drug delivery on rabbit eye." Current eye research, 2010; 35(12): 1081-1089.
49. Khan, Nazia, Mohammed Aqil, Ameeduzzafar, Syed Sarim Imam, and Asgar Ali. "Development and evaluation of a novel in situ gel of sparfloxacin for sustained ocular drug delivery: in vitro and ex vivo characterization." Pharmaceutical development and technology, 2015; 20(6): 662-669.
50. McKenzie, Barbara, Graeme Kay, Kerr H. Matthews, Rachel Knott, and Donald Cairns. "Preformulation of cysteamine gels for treatment of the ophthalmic complications in cystinosis." International journal of pharmaceutics, 2016; 515, no. 1-2: 575-582.
51. Aldrich, D. S., Cynthia M. Bach, William Brown, Wiley Chambers, Jeffrey Fleitman, Desmond Hunt, M. Marques, Y. Mille, A. K. Mitra, and S. M. Platzer. "Ophthalmic preparations." US Pharmacopeia, 2013; 39(5): 1-21.
52. Williams, David, Sheldon Middleton, Hamidreza Fattahian, and Roozbeh Moridpour. "Comparison of hyaluronic acid-containing topical eye drops with carbomer-based topical ocular gel as a tear replacement in canine keratoconjunctivitis sicca: A prospective study in twenty five dogs." In Veterinary Research Forum, vol. 3, no. 4, p. 229. Faculty of Veterinary Medicine, Urmia University, Urmia, Iran, 2012.
53. Obiedallah, Manar M., A. M. Abdel-Mageed, and Tahani H. Elfaham. "Ocular administration of acetazolamide microsponges in situ gel formulations." Saudi Pharmaceutical Journal, 2018; 26(7): 909-920.
54. McMahon, Timothy T., and Karla Zadnik. "Twenty-five years of contact lenses: the impact on the cornea and ophthalmic practice." Cornea, 2000; 19(5): 730-740.
55. Das, Madhusudan, Ms Ankita Sharma, and Mr Kaushal K. Chandrul. "A Review of Potential Effect of Nanotechnology and Control Drug Delivery System Introduce Into Ocular Drug Delivery System." International Journal of Trend in Scientific Research and Development, 2019; 3: 28-34.
56. Cima, Luiza-Madalina, and Ana-Maria Neculai. "Recent biopharmaceutical studies on the evolution of ophthalmic drugs." Eximia, 2022; 4(1): 134-143.
57. Weiner, Alan L., and Brian C. Gilger. "Advancements in ocular drug delivery." Veterinary ophthalmology, 2010; 13(6): 395-406.
58. Al-Kinani, Ali A., Ghada Zidan, Naba Elsaid, Ali Seyfoddin, Adam WG Alani, and Raid G. Alany. "Ophthalmic gels: Past, present and future." Advanced drug delivery reviews, 2018; 126: 113-126.
59. HB, Nirmal, S. Bakliwal, and S. Pawar. "In-situ gel: new trends in controlled and sustained drug delivery system." International Journal of PharmTech Research, 2010; 2(2): 1398-408.
60. Krishnaswami, Venkateshwaran, Ruckmani Kandasamy, Shanmugarathinam Alagarsamy, Rajaguru Palanisamy, and Subramanian Natesan. "Biological macromolecules for ophthalmic drug delivery to treat ocular diseases." International journal of biological macromolecules, 2018; 110: 7-16.
61. Imperiale, Julieta C., Gabriela B. Acosta, and Alejandro Sosnik. "Polymer-based carriers for ophthalmic drug delivery." Journal of controlled release, 2018; 285: 106-141.
62. Sultana, Yasmin, M. Aqil, and Asgar Ali. "Ion-activated, Gelrite®-based in situ ophthalmic gels of pefloxacin mesylate: comparison with conventional eye drops." Drug Delivery, 2006; 13(3): 215-219.
63. Ranch, K., Patel, H., Chavda, L., Koli, A., Maulvi, F. and Parikh, R.K., 2017. Development of in situ ophthalmic gel of dexamethasone sodium phosphate and chloramphenicol: a viable alternative to conventional eye drops. Journal of Applied Pharmaceutical Science, 7(3): 101-108.
64. Patel, Nirav, Vaishali Thakkar, Viral Metalia, Lalji Baldaniya, Tejal Gandhi, and Mukesh Gohel. "Formulation and development of ophthalmic in situ gel for the treatment ocular inflammation and infection using application of quality by design concept." Drug development and industrial pharmacy, 2016; 42(9): 1406-1423.